Notice2024-30320
National Center for Advancing Translational Sciences; Notice of Closed Meetings
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 19, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 244 (Thursday, December 19, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 244 (Thursday, December 19, 2024)]
[Notices]
[Page 103849]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-30320]
[[Page 103849]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; Understudied Proteins R03.
Date: January 2, 2025.
Time: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Center for Advancing Translational Sciences,
National Institutes of Health, 9609 Medical Center Drive, Suite
1E504, Rockville, MD 20892 (Virtual).
Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review
Administrator, Scientific Review Branch Division of Extramural
Activities, National Center for Advancing Translational Sciences,
National Institutes of Health, 9609 Medical Center Drive, Suite
1E504, Bethesda, MD 20892, (301) 402-1744, <a href="/cdn-cgi/l/email-protection#a9cac8dbc6c587c2c0c4e9c7c0c187cec6df"><span class="__cf_email__" data-cfemail="610200130e0d4f0a080c210f08094f060e17">[email protected]</span></a>.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; Review of Limited Competition CTSA
R03 Applications.
Date: January 29, 2025.
Time: 11:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Address: National Center for Advancing Translational Sciences,
National Institutes of Health, 9609 Medical Center Drive, Suite
1E504, Rockville, MD 20892 (Virtual).
Contact Person: Ming Yan, Ph.D., MD, Scientific Review Officer,
Scientific Review Branch Division of Extramural Activities, National
Center for Advancing Translational Sciences, National Institutes of
Health, 9609 Medical Center Drive, Suite 1E504, Bethesda, MD 20892,
(301) 451-2853, <a href="/cdn-cgi/l/email-protection#781511161f5601191638161110561f170e"><span class="__cf_email__" data-cfemail="adc0c4c3ca83d4ccc3edc3c4c583cac2db">[email protected]</span></a>.
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: December 16, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-30320 Filed 12-18-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 19, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.